

# Alexandre A A JÃ;come

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1950235/publications.pdf>

Version: 2024-02-01

38  
papers

523  
citations

687220

13  
h-index

713332

21  
g-index

39  
all docs

39  
docs citations

39  
times ranked

844  
citing authors

#	ARTICLE	IF	CITATIONS
1	A comprehensive framework for early-onset colorectal cancer research. <i>Lancet Oncology</i> , The, 2022, 23, e116-e128.	5.1	49
2	Treatment patterns and outcomes of patients with metastatic colorectal cancer in third-line and beyond systemic therapy: Real-world data from a setting with limited resources.. <i>Journal of Clinical Oncology</i> , 2022, 40, 58-58.	0.8	0
3	The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1073-1085.	1.3	4
4	Anal Cancer: Emerging Standards in a Rare Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 2774-2788.	0.8	13
5	The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. <i>British Journal of Cancer</i> , 2021, 124, 797-804.	2.9	16
6	Brazilian Group of Gastrointestinal Tumoursâ€™ consensus guidelines for the management of oesophageal cancer. <i>Eancermedalscience</i> , 2021, 15, 1195.	0.6	1
7	Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil. <i>JCO Global Oncology</i> , 2021, 7, 46-55.	0.8	36
8	Emerging and Experimental Agents for Anal Cancer: What is New?. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 433-440.	1.5	7
9	Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. <i>Clinical Cancer Research</i> , 2021, 27, 3414-3421.	3.2	25
10	Machine learning prediction of COVID-19 mortality in cancer patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1558-1558.	0.8	0
11	Predictors of home death and the quality of end-of-life care at a cancer center in Brazil.. <i>Journal of Clinical Oncology</i> , 2021, 39, e24004-e24004.	0.8	1
12	Effect of Adding Bevacizumab to Chemotherapy on Pathologic Response to Preoperative Systemic Therapy for Resectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2021, 20, 265-272.	1.0	7
13	Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2136128.	2.8	29
14	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. <i>British Journal of Cancer</i> , 2020, 123, 1262-1270.	2.9	18
15	Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 901-908.	1.1	7
16	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. <i>Clinical Colorectal Cancer</i> , 2020, 19, e189-e199.	1.0	1
17	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	1.0	3
18	Brazilian Group of Gastrointestinal Tumoursâ€™ consensus guidelines for the management of gastric cancer. <i>Eancermedalscience</i> , 2020, 14, 1126.	0.6	3

#	ARTICLE	IF	CITATIONS
19	A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. <i>Clinical Colorectal Cancer</i> , 2019, 18, 301-306.	1.0	7
20	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263.	1.4	29
21	Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	12
22	Prognostic value of genomic alterations (GA) on overall survival in appendiceal adenocarcinoma (AA).. <i>Journal of Clinical Oncology</i> , 2019, 37, 554-554.	0.8	0
23	FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15060-e15060.	0.8	0
24	Experimental and investigational drugs for the treatment of anal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 941-950.	1.9	4
25	Epstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease?. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2016, 49, 150-157.	0.4	25
26	Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E970-80.	0.9	13
27	Development of a new multimedia instrument to measure cancer-specific quality of life in Portuguese-speaking patients with varying literacy skills. <i>SpringerPlus</i> , 2016, 5, 972.	1.2	4
28	Personalized medicine in gastric cancer: Where are we and where are we going?. <i>World Journal of Gastroenterology</i> , 2016, 22, 1160.	1.4	37
29	Adjuvant therapy for gastric cancer: What have we learned since INT0116?. <i>World Journal of Gastroenterology</i> , 2015, 21, 3850.	1.4	13
30	Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. <i>Gastric Cancer</i> , 2014, 17, 76-86.	2.7	35
31	Consensus of the Brazilian Society of Infectious Diseases and Brazilian Society of Clinical Oncology on the management and treatment of Kaposi's sarcoma. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 315-326.	0.3	15
32	Mixture and non-mixture cure fraction models based on the generalized modified Weibull distribution with an application to gastric cancer data. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 112, 343-355.	2.6	47
33	Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy. <i>Gastric Cancer</i> , 2013, 16, 233-238.	2.7	20
34	Imatinib-Induced Bone Edema: Case Report and Review of Literature. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1187-1191.	2.3	5
35	HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. <i>World Journal of Gastroenterology</i> , 2013, 19, 6438.	1.4	27
36	Prognostic value of epidermal growth factor receptors (EGFR) on overall survival of gastric cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14599-e14599.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Watch and wait policy remains experimental for the management of rectal cancer. Colorectal Disease, 2010, 12, 833-833.	0.7	7
38	More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology. European Medical Journal Oncology, 0, , 43-52.	0.0	1